{"id":49466,"date":"2022-10-11T11:01:58","date_gmt":"2022-10-11T09:01:58","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/apollo-health-ventures-and-paul-scherrer-institute-launch-focal-biosciences\/"},"modified":"2022-10-11T11:01:58","modified_gmt":"2022-10-11T09:01:58","slug":"apollo-health-ventures-and-paul-scherrer-institute-launch-focal-biosciences","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/apollo-health-ventures-and-paul-scherrer-institute-launch-focal-biosciences\/","title":{"rendered":"Apollo Health Ventures and Paul Scherrer Institute Launch Focal Biosciences"},"content":{"rendered":"
\n

\n– Newly established Focal Biosciences will focus on bringing together leading experts and scientific discoveries to harness cellular reprogramming in the fight against common age-related diseases\n<\/p>\n

BOSTON & BERLIN & VILLIGEN, Switzerland–(BUSINESS WIRE)–Apollo Health Ventures<\/a> and the Paul Scherrer Institute (PSI) launched Focal Biosciences. The newly established biotech company aims to redefine the treatment of age-related diseases by reprogramming deregulated cell states that drive the detrimental processes underlying many serious diseases of aging that represent a significant health burden.\n<\/p>\n

<\/a><\/p>\n

\nApollo Health Ventures and the Paul Scherrer Institute will join their resources together with scientific founder Prof. G.V. Shivashankar, Head of the Laboratory of Nanoscale Biology, Paul Scherrer Institute and Professor of Mechano-Genomics, ETH Zurich, a recognized leader in mechanogenomics with strong expertise in cellular reprogramming. The newly founded entity will initially operate out of the Paul Scherrer Institute, the largest research institute for natural and engineering sciences in Switzerland that serves scientists around the world by accommodating highly complicated experiments in their industry-leading research facilities. Focal Biosciences thereby has access to PSI\u2019s key infrastructure and expertise as part of Apollo’s venture creation program, \u201cVenture Labs\u201d that sources leading science from scientists and labs in Europe and North America, based on its deep understanding of the biology of aging.\n<\/p>\n

\n\u201cOur investment approach is focused on identifying outstanding science to catalyze and build transformational companies and taking an active role in their corporate evolution. We have watched the formation and maturation of the cellular reprogramming space for some time,\u201d said Jan Adams, Venture Partner at Apollo Health Ventures.<\/b> \u201cWe are confident that with the expertise and technologies developed by Prof. Shivashankar at PSI, Focal Biosciences is pursuing a unique and innovative approach leveraging an advanced concept of cellular reprogramming, that will enable the development of a novel class of therapies.\u201d\n<\/p>\n

\n\u201cWe value Apollo Health Ventures\u2019 and PSI\u2019s commitment to our scientific vision of how to fundamentally change the treatment landscape for a variety of age-related diseases,\u201d said Prof. G.V. Shivashankar, Scientific Founder of Focal Biosciences, Head of the Laboratory of Nanoscale Biology, Paul Scherrer Institute and Professor of Mechano-Genomics, ETH Zurich<\/b>. \u201cI look forward to working with the expert team at Apollo to position Focal Biosciences for success and build a company that trailblazes a new path for patients with severe diseases.\u201d\n<\/p>\n

\nAdvances in understanding the biology of aging coupled with emerging technologies have significantly increased pre-symptomatic detection of age-related damage and dysfunction and paved the way for novel interventions. Cellular reprogramming in particular provides a novel approach of resetting damaged or dysfunctional cells to a healthy state, reversing disease mechanisms and stopping detrimental processes to transform the treatment landscape of age-related diseases.\n<\/p>\n

\nAbout Focal Biosciences<\/i>\n<\/p>\n

\nFocal Biosciences is redefining the treatment of age-related diseases by applying its deep scientific expertise in the mechanisms of cellular reprograming to reverse detrimental disease processes and restore health.\n<\/p>\n

\nAbout Apollo Health Ventures<\/i>\n<\/p>\n

\nApollo Health Ventures is a transatlantic venture capital firm specialized in developing and investing in data-driven biotechnology and health tech ventures. Apollo Health Ventures invests in game-changing companies at the seed or early stage and builds companies within the aging sector. Apollo\u2019s team consists of entrepreneurs, seasoned biotech investors and scientists with remarkable track records in life science investments and venture creation.\n<\/p>\n

\nAbout Paul Scherrer Institute<\/i>\n<\/p>\n

\nThe Paul Scherrer Institute (PSI) develops, builds and operates large, complex research facilities and makes them available to the national and international research community. The institute’s own key research priorities are in the fields of matter and materials, energy and environment and human health. PSI is committed to the training of future generations. Therefore, about one quarter of our staff are post-docs, post-graduates or apprentices. Altogether PSI employs 2200 people, thus being the largest research institute in Switzerland. The annual budget amounts to approximately CHF 400 million. PSI is part of the ETH Domain, with the other members being the two Swiss Federal Institutes of Technology, ETH Zurich and EPFL Lausanne, as well as Eawag (Swiss Federal Institute of Aquatic Science and Technology), Empa (Swiss Federal Laboratories for Materials Science and Technology) and WSL (Swiss Federal Institute for Forest, Snow and Landscape Research).\n<\/p>\n

Contacts<\/b> <\/p>\n

\nApollo Health Ventures<\/i>
Dr. Jan Adams<\/b>
Venture Partner
\n
jan@apollo.vc <\/a>\n<\/p>\n

\nTrophic Communications<\/b>
Stephanie May & Eva Mulder
\n
+49 89 238 877 30
\n
apollo@trophic.eu<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

– Newly established Focal Biosciences will focus on bringing together leading experts and scientific discoveries to harness cellular reprogramming in the fight against common age-related diseases BOSTON & BERLIN & VILLIGEN, Switzerland–(BUSINESS WIRE)–Apollo Health Ventures and the Paul Scherrer Institute (PSI) launched Focal Biosciences. The newly established biotech company aims to redefine the treatment of … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-49466","6":"format-standard","7":"category-industry"},"yoast_head":"\nApollo Health Ventures and Paul Scherrer Institute Launch Focal Biosciences - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/apollo-health-ventures-and-paul-scherrer-institute-launch-focal-biosciences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Apollo Health Ventures and Paul Scherrer Institute Launch Focal Biosciences - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"– Newly established Focal Biosciences will focus on bringing together leading experts and scientific discoveries to harness cellular reprogramming in the fight against common age-related diseases BOSTON & BERLIN & VILLIGEN, Switzerland–(BUSINESS WIRE)–Apollo Health Ventures and the Paul Scherrer Institute (PSI) launched Focal Biosciences. The newly established biotech company aims to redefine the treatment of ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/apollo-health-ventures-and-paul-scherrer-institute-launch-focal-biosciences\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-11T09:01:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221011005182\/en\/1596607\/21\/5ff3c7ea826b138ee7c35511_apollo-dark-png.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/apollo-health-ventures-and-paul-scherrer-institute-launch-focal-biosciences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/apollo-health-ventures-and-paul-scherrer-institute-launch-focal-biosciences\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Apollo Health Ventures and Paul Scherrer Institute Launch Focal Biosciences\",\"datePublished\":\"2022-10-11T09:01:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/apollo-health-ventures-and-paul-scherrer-institute-launch-focal-biosciences\\\/\"},\"wordCount\":725,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/apollo-health-ventures-and-paul-scherrer-institute-launch-focal-biosciences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221011005182\\\/en\\\/1596607\\\/21\\\/5ff3c7ea826b138ee7c35511_apollo-dark-png.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/apollo-health-ventures-and-paul-scherrer-institute-launch-focal-biosciences\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/apollo-health-ventures-and-paul-scherrer-institute-launch-focal-biosciences\\\/\",\"name\":\"Apollo Health Ventures and Paul Scherrer Institute Launch Focal Biosciences - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/apollo-health-ventures-and-paul-scherrer-institute-launch-focal-biosciences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/apollo-health-ventures-and-paul-scherrer-institute-launch-focal-biosciences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221011005182\\\/en\\\/1596607\\\/21\\\/5ff3c7ea826b138ee7c35511_apollo-dark-png.jpg\",\"datePublished\":\"2022-10-11T09:01:58+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/apollo-health-ventures-and-paul-scherrer-institute-launch-focal-biosciences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/apollo-health-ventures-and-paul-scherrer-institute-launch-focal-biosciences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/apollo-health-ventures-and-paul-scherrer-institute-launch-focal-biosciences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221011005182\\\/en\\\/1596607\\\/21\\\/5ff3c7ea826b138ee7c35511_apollo-dark-png.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221011005182\\\/en\\\/1596607\\\/21\\\/5ff3c7ea826b138ee7c35511_apollo-dark-png.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/apollo-health-ventures-and-paul-scherrer-institute-launch-focal-biosciences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Apollo Health Ventures and Paul Scherrer Institute Launch Focal Biosciences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Apollo Health Ventures and Paul Scherrer Institute Launch Focal Biosciences - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/apollo-health-ventures-and-paul-scherrer-institute-launch-focal-biosciences\/","og_locale":"en_US","og_type":"article","og_title":"Apollo Health Ventures and Paul Scherrer Institute Launch Focal Biosciences - Pharma Trend","og_description":"– Newly established Focal Biosciences will focus on bringing together leading experts and scientific discoveries to harness cellular reprogramming in the fight against common age-related diseases BOSTON & BERLIN & VILLIGEN, Switzerland–(BUSINESS WIRE)–Apollo Health Ventures and the Paul Scherrer Institute (PSI) launched Focal Biosciences. The newly established biotech company aims to redefine the treatment of ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/apollo-health-ventures-and-paul-scherrer-institute-launch-focal-biosciences\/","og_site_name":"Pharma Trend","article_published_time":"2022-10-11T09:01:58+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221011005182\/en\/1596607\/21\/5ff3c7ea826b138ee7c35511_apollo-dark-png.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/apollo-health-ventures-and-paul-scherrer-institute-launch-focal-biosciences\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/apollo-health-ventures-and-paul-scherrer-institute-launch-focal-biosciences\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Apollo Health Ventures and Paul Scherrer Institute Launch Focal Biosciences","datePublished":"2022-10-11T09:01:58+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/apollo-health-ventures-and-paul-scherrer-institute-launch-focal-biosciences\/"},"wordCount":725,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/apollo-health-ventures-and-paul-scherrer-institute-launch-focal-biosciences\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221011005182\/en\/1596607\/21\/5ff3c7ea826b138ee7c35511_apollo-dark-png.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/apollo-health-ventures-and-paul-scherrer-institute-launch-focal-biosciences\/","url":"https:\/\/pharma-trend.com\/en\/apollo-health-ventures-and-paul-scherrer-institute-launch-focal-biosciences\/","name":"Apollo Health Ventures and Paul Scherrer Institute Launch Focal Biosciences - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/apollo-health-ventures-and-paul-scherrer-institute-launch-focal-biosciences\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/apollo-health-ventures-and-paul-scherrer-institute-launch-focal-biosciences\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221011005182\/en\/1596607\/21\/5ff3c7ea826b138ee7c35511_apollo-dark-png.jpg","datePublished":"2022-10-11T09:01:58+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/apollo-health-ventures-and-paul-scherrer-institute-launch-focal-biosciences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/apollo-health-ventures-and-paul-scherrer-institute-launch-focal-biosciences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/apollo-health-ventures-and-paul-scherrer-institute-launch-focal-biosciences\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221011005182\/en\/1596607\/21\/5ff3c7ea826b138ee7c35511_apollo-dark-png.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221011005182\/en\/1596607\/21\/5ff3c7ea826b138ee7c35511_apollo-dark-png.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/apollo-health-ventures-and-paul-scherrer-institute-launch-focal-biosciences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Apollo Health Ventures and Paul Scherrer Institute Launch Focal Biosciences"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49466","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=49466"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49466\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=49466"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=49466"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=49466"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}